Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -749 Million USD | -446.72% |
| 2023 | -137 Million USD | -139.26% |
| 2022 | 349 Million USD | -1.41% |
| 2021 | 354 Million USD | 146.18% |
| 2020 | 143.8 Million USD | 132.69% |
| 2019 | 61.8 Million USD | -77.2% |
| 2018 | 271.1 Million USD | 15.76% |
| 2017 | 234.2 Million USD | 7.53% |
| 2016 | 217.8 Million USD | -16.2% |
| 2015 | 259.9 Million USD | 7.89% |
| 2014 | 240.9 Million USD | 17.86% |
| 2013 | 204.4 Million USD | 3.23% |
| 2012 | 198 Million USD | 6.39% |
| 2011 | 186.1 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -16 Million USD | 97.82% |
| 2024 FY | 145 Million USD | 205.84% |
| 2024 Q3 | -17 Million USD | -6.25% |
| 2024 Q4 | 160 Million USD | 1041.18% |
| 2024 Q1 | -735 Million USD | -635.0% |
| 2023 Q4 | -100 Million USD | -300.0% |
| 2023 Q3 | -25 Million USD | -118.12% |
| 2023 Q2 | 138 Million USD | 130.0% |
| 2023 FY | -137 Million USD | -139.26% |
| 2023 Q1 | 60 Million USD | -75.61% |
| 2022 Q3 | 211 Million USD | 31.06% |
| 2022 FY | 349 Million USD | -1.41% |
| 2022 Q1 | 138 Million USD | -45.02% |
| 2022 Q4 | 246 Million USD | 16.59% |
| 2022 Q2 | 161 Million USD | 16.67% |
| 2021 Q4 | 251 Million USD | -31.9% |
| 2021 FY | 354 Million USD | 146.18% |
| 2021 Q3 | 368.6 Million USD | 191.15% |
| 2021 Q1 | 81.5 Million USD | -52.12% |
| 2021 Q2 | 126.6 Million USD | 55.34% |
| 2020 FY | 143.8 Million USD | 132.69% |
| 2020 Q3 | 100.8 Million USD | 13.26% |
| 2020 Q2 | 89 Million USD | 158.72% |
| 2020 Q4 | 170.2 Million USD | 68.85% |
| 2020 Q1 | 34.4 Million USD | -68.58% |
| 2019 FY | 61.8 Million USD | -77.2% |
| 2019 Q1 | 20.4 Million USD | -79.03% |
| 2019 Q2 | 78.2 Million USD | 283.33% |
| 2019 Q3 | 65.8 Million USD | -15.86% |
| 2019 Q4 | 109.5 Million USD | 66.41% |
| 2018 Q1 | 31.9 Million USD | -67.08% |
| 2018 Q4 | 97.3 Million USD | 33.11% |
| 2018 Q3 | 73.1 Million USD | 6.25% |
| 2018 Q2 | 68.8 Million USD | 115.67% |
| 2018 FY | 271.1 Million USD | 15.76% |
| 2017 Q2 | 47.9 Million USD | 93.15% |
| 2017 Q3 | 64.6 Million USD | 34.86% |
| 2017 Q4 | 96.9 Million USD | 50.0% |
| 2017 FY | 234.2 Million USD | 7.53% |
| 2017 Q1 | 24.8 Million USD | -72.69% |
| 2016 FY | 217.8 Million USD | -16.2% |
| 2016 Q2 | 58.6 Million USD | 57.95% |
| 2016 Q4 | 90.8 Million USD | 188.25% |
| 2016 Q1 | 37.1 Million USD | -58.41% |
| 2016 Q3 | 31.5 Million USD | -46.25% |
| 2015 FY | 259.9 Million USD | 7.89% |
| 2015 Q4 | 89.2 Million USD | 35.56% |
| 2015 Q1 | 42.5 Million USD | -57.96% |
| 2015 Q3 | 65.8 Million USD | 5.45% |
| 2015 Q2 | 62.4 Million USD | 46.82% |
| 2014 Q2 | 44.5 Million USD | 26.78% |
| 2014 FY | 240.9 Million USD | 17.86% |
| 2014 Q3 | 60.2 Million USD | 35.28% |
| 2014 Q1 | 35.1 Million USD | -55.29% |
| 2014 Q4 | 101.1 Million USD | 67.94% |
| 2013 Q3 | 47.9 Million USD | 5.04% |
| 2013 Q4 | 78.5 Million USD | 63.88% |
| 2013 FY | 204.4 Million USD | 3.23% |
| 2013 Q1 | 32.4 Million USD | 0.0% |
| 2013 Q2 | 45.6 Million USD | 40.74% |
| 2012 FY | 198 Million USD | 6.39% |
| 2011 FY | 186.1 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 204.37 Million USD | 466.485% |
| Bausch Health Companies Inc. | 963 Million USD | 177.778% |
| Emergent BioSolutions Inc. | -726.4 Million USD | -3.111% |
| Elanco Animal Health Incorporated | 326 Million USD | 329.755% |
| Perrigo Company plc | 151.9 Million USD | 593.088% |
| Teva Pharmaceutical Industries Limited | 433 Million USD | 272.979% |
| Zoetis Inc. | 3.06 Billion USD | 124.405% |